Novartis

NVS

Market cap $287B

The Dividend Income Accelerator Portfolio emphasizes high-quality companies with sustainable dividends, strong balance sheets, and attractive valuations to optimize risk-adjusted returns. I prioritize a diversified mix of ETFs and individual stocks across sectors, balancing dividend income, growth, and capital appreciation while mitigating downside risk. Key metrics include a 3.75% weighted average dividend yield, low payout ratios, and low beta factors, supporting long-term portfolio resilience.

Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growth innovative assets.

Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.

My 21% yielding ETF portfolio continues to outperform major benchmarks in yield and total return, with recent strategic additions enhancing diversification. I replaced funds (AMZP, NVHE.U) with better suited ETFs, including quality Canadian and international equities with covered call overlays and modest leverage. New positions like CANY:CA, SIXY:CA, INTY:CA, YNVD:CA, YAVG:CA, and TDAX/TDAQ target sustainable high income, robust EPS growth, and exposure to leading sectors.

Novartis continues to favor in-licensing and bolt-on acquisitions. The Myricx Bio acquisition expands Novartis' ADC pipeline with novel NMTi payloads, but commercial impact is several years away. Avidity's del-brax and Ionis's pelacarsen, both late-stage assets, offer multibillion-dollar peak sales potential with pivotal data expected in the second half of the year.

NVS plans to acquire Myricx Bio for up to $1.5 billion, adding novel ADC technology to expand its oncology pipeline and tumor targets.

The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis's oncology capabilities.

Swiss drugmaker Novartis said on Monday it had ​agreed to pay up to $1.5 ‌billion for U.K.-based biotechnology firm Myricx Bio in a deal expected ​to close in the second ​half of 2026.

Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.

The first half of the year is over, and it may surprise some investors that European stocks are nearly at parity with U.S. stocks. The tale of the tape as of June 30 tells the story: